Citadel Advisors
IRD

Citadel Advisors’s Opus Genetics IRD Stock Holding History

Citadel Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,000
Closed -$17.9K – 14465
2025
Q2 		$17.9K Buy
19,000
+5,300
+39% +$4.91K ﹤0.01% 12126
2025
Q1 		$13.5K Buy
13,700
+1,100
+9% +$1.23K ﹤0.01% 13400
2024
Q4 		$15K Sell
12,600
-1,500
-11% -$1.72K ﹤0.01% 13380
2024
Q3 		$18.5K Buy
14,100
+12,100
+605% +$18.6K ﹤0.01% 12840
2024
Q2 		$3.06K Sell
2,000
-1,600
-44% -$2.77K ﹤0.01% 13627
2024
Q1 		$7.24K Sell
3,600
-7,600
-68% -$19.3K ﹤0.01% 13626
2023
Q4 		$33.7K Sell
11,200
-34,700
-76% -$103K ﹤0.01% 12169
2023
Q3 		$154K Buy
45,900
+29,000
+172% +$116K ﹤0.01% 10314
2023
Q2 		$73.3K Buy
16,900
+3,900
+30% +$18.5K ﹤0.01% 11338
2023
Q1 		$48.8K Buy
13,000
+10,500
+420% +$37.7K ﹤0.01% 12185
2022
Q4 		$8.82K Sell
2,500
-22,500
-90% -$59.2K ﹤0.01% 13727
2022
Q3 		$50K Sell
25,000
-2,600
-9% -$5.61K ﹤0.01% 11631
2022
Q2 		$53K Sell
27,600
-5,400
-16% -$12.3K ﹤0.01% 11901
2022
Q1 		$107K Buy
33,000
+12,000
+57% +$41.1K ﹤0.01% 12228
2021
Q4 		$78K Sell
21,000
-11,500
-35% -$46.1K ﹤0.01% 12966
2021
Q3 		$167K Buy
+32,500
New +$150K ﹤0.01% 12229

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors's IRD Position: Q1 2026 in Review

Citadel Advisors reduced its Opus Genetics (IRD) stake by 33% in Q1 2026, selling an estimated $207K and leaving 120,900 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #9066.

Citadel Advisors first reported a position in IRD in Q2 2013 and has held it in 28 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Citadel Advisors held 120,900 shares of Opus Genetics worth $550K as of Q1 2026.
  • Citadel Advisors sold 59,821 Opus Genetics shares in Q1 2026, an estimated $207K.
  • Opus Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9066 holding.
  • Citadel Advisors first reported a position in Opus Genetics in Q2 2013 and has held it in 28 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.